IIB 
115TH CONGRESS 
2D SESSION 
H. R. 1660 
IN THE SENATE OF THE UNITED STATES 
JANUARY 19, 2018 
Received; read twice and referred to the Committee on Foreign Relations 
AN ACT 
To direct the Administrator of the United States Agency 
for International Development to submit to Congress a 
report on the development and use of global health inno-
vations in the programs, projects, and activities of the 
Agency. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Sep 11 2014 
05:12 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1660.RFS
H1660
SSpencer on DSKBBXCHB2PROD with BILLS
HR 1660 RFS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Global Health Innova-
tion Act of 2017’’. 
SEC. 2. ANNUAL REPORT. 
(a) IN GENERAL.—Not later than 180 days after the 
date of the enactment of this Act, and annually thereafter 
for a period of 4 years, the Administrator of the United 
States Agency for International Development shall submit 
to Congress a report on the development and use of global 
health innovations in the programs, projects, and activities 
of the Agency. 
(b) MATTERS TO BE INCLUDED.—The report re-
quired by subsection (a) shall include the following: 
(1) A description of— 
(A) the extent to which global health inno-
vations described in subsection (a) include 
drugs, diagnostics, devices, vaccines, electronic 
and mobile health technologies, and related be-
havior change and service delivery innovations; 
(B) how innovation has advanced the 
Agency’s commitments to achieving an HIV/ 
AIDS-free generation, ending preventable child 
and maternal deaths, and protecting commu-
nities from infectious diseases, as well as 
furthered by the Global Health Strategic 
Framework; 
VerDate Sep 11 2014 
05:12 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1660.RFS
H1660
SSpencer on DSKBBXCHB2PROD with BILLS
HR 1660 RFS
(C) how goals are set for health product 
development in relation to the Agency’s health- 
related goals and how progress and impact are 
measured towards those goals; 
(D) how the Agency’s investments in inno-
vation relate to its stated goals; and 
(E) progress made towards health product 
development goals. 
(2) How the Agency, both independently and 
with partners, donors, and public-private partner-
ships, is— 
(A) leveraging United States investments 
to achieve greater impact in health innovation; 
(B) engaging in activities to develop, ad-
vance, and introduce affordable, available, and 
appropriate global health products; and 
(C) scaling up appropriate health innova-
tions in the development pipeline. 
(3) A description of collaboration and coordina-
tion with other Federal departments and agencies, 
including the Centers for Disease Control and Pre-
vention, in support of global health product develop-
ment, including a description of how the Agency is 
working to ensure critical gaps in product develop-
ment for global health are being filled. 
VerDate Sep 11 2014 
05:12 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1660.RFS
H1660
SSpencer on DSKBBXCHB2PROD with BILLS
HR 1660 RFS
(4) A description of how the Agency is coordi-
nating and aligning global health innovation activi-
ties between the Global Development Lab, the Cen-
ter for Accelerating Innovation and Impact, and the 
Bureau for Global Health. 
Passed the House of Representatives January 18, 
2018. 
Attest: 
KAREN L. HAAS, 
Clerk. 
VerDate Sep 11 2014 
05:12 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1660.RFS
H1660
SSpencer on DSKBBXCHB2PROD with BILLS